Amisulpride, recently introduced atypical antipsychotic, is well-known for its broad spectrum effectiveness and lower profile for extrapyramidal side effects (EPS). Its selective affinity for dopamine receptors in the limbic structures, but not in the striatum, leads to a low risk of extrapyramidal side effects. Here, we report two cases of EPS associated with lower dose of amisulpride. The proposed mechanism for its causation is also discussed. Authors invite more studies, specifically from the Indian context to find out the incidence of EPS and other associated side effects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052967 | PMC |
http://dx.doi.org/10.4103/0253-7176.191391 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!